Machine Learning in Amyotrophic Lateral Sclerosis: Achievements, Pitfalls, and Future Directions
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Amyotrophic Lateral Sclerosis (ALS) is a relentlessly progressive neurodegenerative condition with limited therapeutic options at present. Survival from symptom onset ranges from three to five years depending on genetic, demographic and phenotypic factors. Despite tireless research efforts, the core aetiology of the disease remains elusive and drug development efforts are confounded by the lack of accurate monitoring markers. Disease heterogeneity, late-stage recruitment into pharmaceutical trials, and inclusion of phenotypically admixed patient cohorts are some of the key barriers to successful clinical trials. Machine Learning (ML) models and large international data sets offer unprecedented opportunities to appraise candidate diagnostic, monitoring and prognostic markers. Accurate patient stratification into well-defined prognostic categories is another aspiration of emerging classification and staging systems Methods The objective of this paper is the comprehensive, systematic and critical review of ML initiatives in ALS to date and their potential in research, clinical and pharmacological applications. The focus of this review is to provide a dual, clinical-mathematical perspective on recent advances and future directions of the field. Another objective of the paper is the frank discussion of the pitfalls and drawbacks of specific models, highlighting the shortcomings of existing studies and to provide methodological recommendations for future study designs. Results Despite considerable sample size limitations, ML techniques have already been successfully applied to ALS data sets and a number of promising diagnosis models have been proposed. Prognostic models have been tested using core clinical variables, biological and neuroimaging data. These models also offer patient stratification opportunities for future clinical trials. Despite the enormous potential of ML in ALS research, statistical assumptions are often violated, the choice of specific statistical models is seldom justified, and the constraints of ML models are rarely enunciated. Conclusions From a mathematical perspective, the main barrier to the development of validated diagnostic, prognostic and monitoring indicators stem from limited sample sizes. The combination of multiple clinical, biofluid and imaging biomarkers is likely to increase the accuracy of mathematical modelling and contribute to optimised clinical trial designs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Breiman, L. (2001) · Machine Learning · doi:10.1023/a:1010933404324 · Cited by 133,538
Dermatologist-level classification of skin cancer with deep neural networks
Esteva, A., Kuprel, B., Novoa, R. A., Ko, J., Swetter, S. M., Blau, H. M., & Thrun, S. (2017) · Nature · doi:10.1038/nature21056 · Cited by 14,362
Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis
Neumann, M., Sampathu, D. M., Kwong, L. K., Truax, A. C., Micsenyi, M. C., Chou, T. T., Bruce, J., Schuck, T., Grossman, M., Clark, C. M., et al. (2006) · Science · doi:10.1126/science.1134108 · Cited by 6,576 · cited 1×
“The accumulation of the Transactive Response DNA Binding Protein 43 ( TDP-43 ) is the most consistent pathological finding in approximately 95% of ALS cases (Neumann et al., 2006).”
BackgroundEl Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis
Brooks, B. R., Miller, R. G., Swash, M., & Munsat, T. L. (2000) · Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders · doi:10.1080/146608200300079536 · Cited by 5,433 · cited 1×
“Patients are formally diagnosed based on the revised El Escorial criteria (Brooks, 1994; Brooks et al., 2000; de Carvalho et al., 2008) which achieve low false negative rates (0.5%), but suffer from relatively high false positive rates (57”
BackgroundInfluentialExplanation in artificial intelligence: Insights from the social sciences
Miller, T. (2019) · Artificial Intelligence · doi:10.1016/j.artint.2018.07.007 · Cited by 5,302
Moons, K. G. M., Altman, D. G., Reitsma, J. B., Ioannidis, J. P. A., Macaskill, P., Steyerberg, E. W., Vickers, A. J., Ransohoff, D. F., & Collins, G. S. (2015) · Annals of Internal Medicine · doi:10.7326/m14-0698 · Cited by 5,147 · cited 2×
“General reporting guidelines for model design and model evaluation are summarized in the Transparent Reporting of a multivariate prediction model for Individual Prognosis or Diagnosis, or TRIPOD, statement (Moons et al., 2015).”
MethodAUC: A misleading measure of the performance of predictive distribution models
Lobo, J. M., Jiménez‐Valverde, A., & Real, R. (2008) · Global Ecology and Biogeography · doi:10.1111/j.1466-8238.2007.00358.x · Cited by 3,499
Machine Learning Applications in Cancer Prognosis and Prediction
Kourou, K., Exarchos, T. P., Exarchos, K. P., Karamouzis, M. V., & Fotiadis, D. I. (2015) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2014.11.005 · Cited by 3,338 · cited 1×
“In medicine, it has promising diagnostic, prognostic, and risk stratification applications and it has been particularly successful in medical oncology (Kourou et al., 2015).”
BackgroundCedarbaum, J. M., Stambler, N., Malta, E., Fuller, C., Hilt, D., Thurmond, B., & Nakanishi, A. (1999) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(99)00210-5 · Cited by 3,307
Assessing Bias in Studies of Prognostic Factors
Hayden, J. A., van der Windt, D. A., Cartwright, J. L., Côté, P., & Bombardier, C. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-158-4-201302190-00009 · Cited by 3,287 · cited 1×
“The four most common types of bias include: study participation bias, study attrition bias , prognostic factor measurement bias, and outcome measurement bias (Hayden et al., 2013).”
Background
Cited by
Applications of machine learning to diagnosis and treatment of neurodegenerative diseases
Myszczynska, M. A., Ojamies, P. N., Lacoste, A. M. B., Neil, D., Saffari, A., Mead, R., Hautbergue, G. M., Holbrook, J. D., & Ferraiuolo, L. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0377-8 · Cited by 595
Recent advances in the diagnosis and prognosis of amyotrophic lateral sclerosis
Goutman, S. A., Hardiman, O., Al-Chalabi, A., Chió, A., Savelieff, M. G., Kiernan, M. C., & Feldman, E. L. (2022) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00465-8 · Cited by 493
Emerging insights into the complex genetics and pathophysiology of amyotrophic lateral sclerosis
Goutman, S. A., Hardiman, O., Al-Chalabi, A., Chió, A., Savelieff, M. G., Kiernan, M. C., & Feldman, E. L. (2022) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00414-2 · Cited by 401
Machine learning in concrete science: applications, challenges, and best practices
Li, Z., Yoon, J., Zhang, R., Rajabipour, F., Srubar III, W. V., Dabo, I., & Radlińska, A. (2022) · npj Computational Materials · doi:10.1038/s41524-022-00810-x · Cited by 388
Success stories of AI in drug discovery - where do things stand?
Mak, K.-K., Balijepalli, M. K., & Pichika, M. R. (2022) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2022.1985108 · Cited by 51
Metadata
- Authors
- Grollemund, V., Pradat, P.-F., Querin, G., Delbot, F., Le Chat, G., Pradat-Peyre, J.-F., & Bede, P.
- Venue
- Frontiers in Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2019-02-28
- Volume
- 13
- Pages
- 135-135
- ISSN
- 1662-453X (ISSN-L)
- OpenAlex
- W2918412837
- Cited by
- 152
- References
- 21
- FWCI
- 12.14
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Machine Learning in Amyotrophic Lateral Sclerosis: Achievements, Pitfalls, and Future Directions. https://app.cochat.ai/papers/10.3389/fnins.2019.00135
- The paper
- Grollemund, V., Pradat, P.-F., Querin, G., Delbot, F., Le Chat, G., Pradat-Peyre, J.-F., & Bede, P. (2019). Machine Learning in Amyotrophic Lateral Sclerosis: Achievements, Pitfalls, and Future Directions. Frontiers in Neuroscience. https://doi.org/10.3389/fnins.2019.00135
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.